Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
135M
-
Number of holders
-
134
-
Total 13F shares, excl. options
-
106M
-
Shares change
-
-10.2M
-
Total reported value, excl. options
-
$329M
-
Value change
-
-$121M
-
Put/Call ratio
-
3.14
-
Number of buys
-
72
-
Number of sells
-
-55
-
Price
-
$3.09
Significant Holders of Tango Therapeutics, Inc. - Common Stock (TNGX) as of Q4 2024
163 filings reported holding TNGX - Tango Therapeutics, Inc. - Common Stock as of Q4 2024.
Tango Therapeutics, Inc. - Common Stock (TNGX) has 134 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 106M shares
of 135M outstanding shares and own 79.03% of the company stock.
Largest 10 shareholders include TRV GP IV, LLC (16.9M shares), TCG Crossover Management, LLC (10.7M shares), EcoR1 Capital, LLC (10.6M shares), Boxer Capital Management, LLC (10.4M shares), Nextech Invest Ltd. (5.53M shares), GILEAD SCIENCES, INC. (4.85M shares), BlackRock, Inc. (4.38M shares), FARALLON CAPITAL MANAGEMENT LLC (4M shares), VANGUARD GROUP INC (3.99M shares), and T. Rowe Price Investment Management, Inc. (3.35M shares).
This table shows the top 134 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.